The Most Undervalued Stock That Could Overdeliver in 2022

Silo Wellness Inc. (CSE: SILO) (OTCQB:SILFF) should be the
one company at the top of every investors watchlist.

If you missed out on the 1,571%, 2,602%, or 3,093% moves that some cann-a-bis stocks made — then you’re about to get a second chance with psych-e-delics.

7 Reasons Why Silo Wellness Inc. Could Generate Unstoppable Growth in 2022

Flying well under the radar, micro-cap stock Silo Wellness Inc is currently only valued at $248,624 according to OTC markets as of 7/7/22 (1)

Recent legalization and rollout of the psych-e-delic dr-ug psi-lo-cybin in Oregon could potentionally trigger considerable demand for a stock, such as Silo Wellness. (2)

Silo Wellness Inc. is the only publicly traded psych-e-delic company, with legal psych-e-delic retreat experience, and a strong connection to Oregon. (3)

The company recently announced plans to create a Psych-e-delic Pharmaceutical Manufacturing portfolio with an acquisition of Dyscovry Science, which focuses on the biosynthetic manufacturing of psilocybin and its derivatives. (4)

Not only has the US FDA been supportive of psychedelics, Johns Hopkins, Yale, Berkeley, and Mount Sinai Hospital are establishing psychedelic divisions. (18)

Plus, there’s been substantial proof psychedelics can help with issues such as depression, anxiety, addiction, obsessive compulsive disorder, and obesity. (19)

In the U.S the psychedelic drug market is expected to grow at a tremendous pace and reach $8.9 billion by 2029 – with some predicting that the psychedelic industry in Oregon alone could quickly grow to $1 billion. (6)

Silo Wellness Inc. The Last Chance To Be First-To-Market, Is Right Now, With Psych-a-delics

The Last Chance To Be First-To-Market, Is Right Now, With Psych-a-delics

On November 3rd, 2020, Oregon made history by becoming the first U.S. state to allow the use of the psych-e-delic dr-ug psi-lo-cybin in supervised facilities when voters approved Measure 109… (7)

The state’s program won’t be up and running until January 2023, and there is a lot of work to do… (7)

But get this…

There is only publicly traded psych-e-delic company with legal psych-e-delic retreat experience and a strong connection to Oregon.

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) is the only publicly-traded company in Oregon: (3)

…Founded by an Oregonian.

…To host a psych-e-delic retreat in Oregon.

…That has legal psi-lo-cybin operations in Jamaica.

When investors realize that Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) could be one of the best ways to participate in the psych-e-delic sector, there is no telling what could happen to the share price of this company.

With some predicting that the psych-e-delic industry in Oregon alone could quickly grow to $1 billion (8)– it won’t be long until savvy investors come looking for a way to play this market like they did the cann-a-bis stocks.

Silo Wellness Inc. Could Be The Best Way To Play The Mush-rooming The Psych-e-delic Market

Silo Wellness Inc. is a true under-the-radar find with a very small market cap.

The market cap is one of the most important metrics that investors look at when deciding whether to invest in a company – a company’s market cap is the total number of its outstanding shares of stock multiplied by the current share price. (9)

…And according to, as of July 7th, 2022, the market cap of Silo Wellness Inc is only $249,624…(1)

However, the market cap doesn’t always tell the whole story.

That’s why small market cap stocks move up fast.

In fact, when you check Silo Wellness Inc.’s price history on, you’ll see that on June 21, 2022, shares of (SILFD) traded as low as $.088. (10)

Then just 9 business days later, on July 5th, on what appears to be very little volume, shares of (SILFD) reached over $.113 for a 28.41% move…(10) (not bad for a few days)

Silo Wellness Inc shares moved 28.41% in 9 days. (10)

And the S&P 500 moved a paltry 1.9% during the same period. (11)

Keep reading to see why Silo Wellness Inc. could be the most undervalued story of the decade…

Did You Miss Out on The Cann-a-bis Green Rush?

In 1996 California became the first state in the U.S. to legalize cann-a-bis for medical use (12) – 10 years later, the cann-a-bis market was literally blazing up the charts and early investors were becoming filthy rich.

Once the cann-a-bis stocks started moving, they didn’t stop – and from 2016 to 2018 more gains were made in the cann-a-bis market than almost any other market in the same 2 year period… (13)

If you were early enough to the “Green Rush” you could have seen gains like this:

  • Aurora Cannabis – up 1,571% (would have turned $2,000 into over $31,000)(13)
  • Canopy Growth Corp – up 2,602% (would have turned $2,000 into over $52,000)(13)
  • MariMed – up 3,093% (would have turned $2,000 into over $61,000)(13)
  • Cronos Group – 3,313% (would have turned $2,000 into over $66,000)(13)
  • Namaste Technologies – 6,750% (would have turned $2,000 into over $135,000)(13)

You would have to agree that these moves were incredible… and probably life changing for some of those who got in early…
But forget about cann-a-bis stocks for now. Those days have come and gone..

Psych-e-delics Are Going Mainstream Getting Support from Wall Street & Congress

If you missed out on the “Green Rush” now is the time to focus on the “Shroom Boom” with Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF).

Psych-e-delics are going mainstream – so much so that several ETF’s have recently been launched to offer investor exposure to the industry. (5)

  • The Advisor Shares Psych-e-delics ETF – is an actively managed pure-play psych-e-delic medicines ETF, with every company within it being a psych-e-delic stock. (5)
  • Horizon’s Psych-e-delic Stock Index is also a pure-play psych-e-delics ETF, with all companies held within it being psych-e-delic stocks, but this one is passively managed. (5)
  • Defiance Next Gen Altered Experience is passively managed based on market cap, this time tracking an index called the BITA Medical Psych-e-delics, Cann-a-abis, and Ket-a-mine Index.(5)
  • The Elemental Advisors PSYK ETF is also passively managed based on market cap, this time tracking the Enhanced Consciousness Index. (5)

The Psych-e-delics market is the Next Big Thing

In the U.S, the psych-e-delic dr-ug market is expected to reach $8.9 billion by 2029. (6)

This is due to the increasing rates of mental health disorders that require psych-e-delic treatments and the increase in governments’ willingness to fund the treatments. (6)

Savvy investors will start to notice the trend here. The anti-depressant dr-ug market is expected to hit $16 billion by 2023 and that legacy industry has been around since the 1950’s…

The psych-e-delic market is the next big thing as big dollars are beginning to pour into the industry… which is expected to reach $8.9 billion by 2029 — not bad for a brand new industry..

Which is why Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) needs to be at the top of your watchlist..

Bipartisan Lawmakers Add Psych-e-delics Reform Amendments To Defense Bill (20)

Bipartisan lawmakers in Congress introduced several drug policy reform amendments in a large-scale advocacy bill to the National Defense Authorization Act.(20)

Banning federal employment discrimination against veterans who use marijuana, providing funding for studies on psych-e-delics’ therapeutic benefits, and allowing US Department of Veterans Affairs doctors to recommend medical cannabis to veterans are part of the proposals included in the amendments.(20)

Psych-e-delics Are Going Mainstream Getting Support from Wall Street & Congress

House Appropriations Committee leadership has taken a special interest in psych-e-delics research this year as they’ve crafted spending bills and reports to fund various federal agencies. (21)

And one of the latest examples of that interest comes from a manager’s amendment to legislation covering the Department of Health and Human Services. (21)

The newly added report language contains two sections addressing the therapeutic potential of psychedelics. (21)

One broadly encourages research into the substances as potential treatment options for post-traumatic stress disorder and severe depression, while the other talks about psychedelics as a possible tool to combat conditions that commonly afflict military veterans. (21)

The measures, adopted by the committee build on other existing drug policy reform provisions of the appropriations bill and report. (21)

But the psych-e-delics language is a positive signal from the committee as far as reform advocates are concerned. (21)

Oregon Is About to Capitalize on a Massive Market

The state of Oregon is pursuing an alternative model in which trained facilitators licensed by the Oregon Health Authority will administer psi-lo-cybin. (22)

Clients seeking access to ‘psi-lo-cybin services’, as they are called in Oregon, need not have a medical diagnosis to participate. (22)

Because clinical-trial participants often report sustained feelings of wellbeing, some believe psi-lo-cybin services could help fill the current gap in preventative mental healthcare. (22)

Oregon is on track to become the first US state to roll out legal psi-lo-cybin, the psych-o-active substance found in “magic” mush-rooms starting in just a few months. (16)

Will the Psych-e-delic Market Explode?

Will there be a state-by-state rollout like what is happening with cann-a-bis?

Or will the future of psych-e-delics be a pure pharma play?

Silo Wellness is the only public company with assets covering both options. (15)

Silo Wellness recently announced plans to create a Psych-e-delic Pharmaceutical Manufacturing and Research Portfolio with a proposed acquisition of Dyscovry Science.

This was a very strategic move by Silo Wellness…

Dyscovry Science focuses on biosynthetic manufacturing of psi-lo-cybin and its derivatives targeting a physiological condition, irritable bowel syndrome. (17)

With Dyscovry’s research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psi-lo-cybin and its potentially novel molecule derivatives. (17)

Dyscovry has embarked on the rigorous scientific investigation of enhanced biosynthesis of psi-lo-cybin as an alternative therapeutic option to both naturally occurring and chemically synthesized psi-lo-cybin. (17)

This will not only allow for the future wide-scale production, but also fuel Dyscovry’s mission to unlock the potential for psi-lo-cybin in addressing a variety of disorders with the goal of developing safe, FDA and Health Canada approved therapies. (17)

Let’s see why Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) could be one of those high potential companies by combining both business models

Silo Wellness Inc. is combining the booming demand for psych-e-delic retreat based healing with the biosynthetic manufacturing of psil-o-cybin for psych-e-delics-inspired medicines. (15)

Silo Wellness is the only public company with assets covering both options. (15)

Portfolio Breakout:
Jamaica Psych-e-delic Wellness Retreat (15)

Flagship first-of-its-kind Jamaica wellness retreat

Conducting legal psi-lo-cybin-and 5-MeO-D-M-T-assisted retreats and mush-room and truffle cultivation workshops. (15)
Silo Wellness held its inaugural psi-lo-cybin wellness retreat in Feb 2021. (15)

Portfolio Breakout:
Oregon Nature-Based Psych-e-delic Ket-a-mine Retreat (15)

The first legal psych-e-delic retreat ever conducted in the U.S.

In 2021, held legal, ket-a-mine-assisted wellness retreats in Oregon under the care of an Oregon physician.(15)
In November 2020, Oregon passed Measure 109 permitting licensed service providers to administer psi-lo-cybin in a facilitated setting. (15)

Portfolio Breakout:
Dyscovry Science* (15)

Biosynthesis Partnership with Canadian Government with plans for:
Cost-Effective/Lower Impact API Manufacturing Alternative to Chemical Synthesis. (15)
Patentable Molecular Cocktails and Chemical Derivatives. (15)
IBS: While other companies only focus on mental health, gut health is where Silo Wellness Inc. will differentiate from other companies. (15)
Controlled Substances DEL License. (15)
University Partner for Trials. (15)

Experienced Leadership Team (15)


Mike Arnold
Founder, CEO, Oregon lawyer

Winfield Ding, CPA, CGA, CFA
Chief Financial Officer

Board of Directors

Gerard Lee
Founder of Dyscovry Science

Michael Hartman
Director and Psi-lo-cybin Nasal Spray Inventor
Winfield Ding, CPA, CGA, CFA

Dr. Simon Bababeygy, M.D.

Gregory Biniowsky
Director. B.C. Lawyer

Mike Arnold

Advisory Board

Dr. Parag Bhatt, Ph.D
Pharmacology. Retreat Intake Coordinator. Chief Science Advisor.

Dr. Joseph Barsuglia, Ph.D
Clinical Advisor. Psych-e-delic Psychology and Bioethics

Michael Hartman
Product Development & Science Advisor. Psi-lo-cybin Nasal Spray Inventor & Inhaled Medicine Expert.

Resources List:
Source 1:

Source 2:

Source 3:

Source 4:

Source 5:

Source 6:

Source 7:

Source 8:

Source 9:

Source 10:

Source 11:

Source 12:

Source 13:

Source 14:

Source 15: (((Upload new SILO PDF)))

Source 16:

Source 17:

Source 18:

Source 19:

Source 20:

Source 21:

Source 22:

Disclaimer –

This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece., owned and operated by Jade Cabbage Media, LLC d/b/a makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold, or held by viewers that learn of the profiled companies through our website.

Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for in an effort to enhance public awareness of Silo Wellness Inc. and its securities. Jade Cabbage Media, LLC d/b/a has received up to $10,000 USD dollars (10/19/22) by Winning Media LLC as a total production budget for this advertising effort. Neither or STOXmedia currently hold the securities of Silo Wellness Inc. and do not currently intend to purchase such securities. The issuer, Silo Wellness Inc. has paid Winning Media LLC the sum total of $120,000 USD total production budget.
This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are several important factors that could cause actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues, and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur.
More information on the Company may be found at readers can review all public filings by the Company at the SEDAR and/or SEC’s EDGAR page. Jade Cabbage Media, LLC d/b/a is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.